Pharmacokinetics, Safety and Efficacy of POL7080 in Patients With Ventilator Associated Pseudomonas Aeruginosa Pneumonia
A Phase II, Open-label, Multi-center Study to Assess Pharmacokinetics (PK), Safety and Efficacy of POL7080 Co-administered With Standard of Care (SoC) Treatment in Patients With Ventilator- Associated Pneumonia (VAP) Due to Suspected or Documented Pseudomonas Aeruginosa Infection.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Athens, Greece
- Attikon University Hospital
-
Athens, Greece
- Hospital EVANGELISMOS
-
Athens, Greece
- Hospital KORGIALENIO-BENAKIO E.E.S
-
Athens, Greece
- SOTIRA Pulmonary Clinic
-
-
-
-
-
Barcelona, Spain
- Hospital Del Mar
-
Barcelona, Spain
- Hospital Clinic
-
Barcelona, Spain
- Hospital Bellvitge
-
Madrid, Spain
- Hospital Clinic San Carlos
-
Tarragona, Spain
- Hospital Joan XXIII
-
Valencia, Spain
- Hospital La Fe
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female patients ≥18 years of age diagnosed with VAP , i.e., pneumonia that arises more than 96 hours after endotracheal intubation documented or suspected to be due to Pseudomonas aeruginosa
- Respiratory specimen suitable for culture and Gram stain collected before starting the treatment
- Written Informed consent from the patient's legally acceptable representative or a relative
Exclusion Criteria:
- Patients with known hypersensitivity to fluoroquinolones, carbapenems, cephalosporin, penicillin (beta-lactam antibiotics) or aminoglycoside antibiotics (i.e. all available SoC antibiotics); patients with a clinically significant history of drug allergies and history of anaphylactic reaction and patients with active allergic conditions at the time of screening
- Known or suspected pulmonary conditions which are likely to interfere with the therapeutic response or might have additional impact on pharmacokinetics
- Patients with Acute Physiology and Chronic Health Evaluation II (APACHE II) score >25
- Presence of septic shock at the time of evaluation for study entry
- History of lung transplant
- Patients with known HIV infection with CD4+ (cluster of differentiation 4) cell count < 200/mm3
- Concomitant morbidity of such severity that the patient is likely to die or present with serious medical conditions within 7 days of study entry
- Patients with impaired renal function
- Patients who are currently enrolled in, or have not yet completed at least 30 days since ending another investigational device or drug trial or are receiving other investigational agent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: POL7080, Anti-pseudomonal antibiotics
POL7080 daily co-administered with standard of care treatment
|
Intravenous infusion
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To measure the plasma concentrations of POL7080
Time Frame: Day 3 and Day 6
|
PK profile of POL7080 will be determined on Day 3 and Day 6.
|
Day 3 and Day 6
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse Events
Time Frame: Daily assessment up to 34 days from informed consent.
|
Number of adverse events reported by the patients or observed by the investigator will be recorded.
Onset, end date, severity, causal relationship, outcome and measures taken will be summarized.
Death, discontinuations and serious adverse events will be listed and narrative summaries will be provided.
|
Daily assessment up to 34 days from informed consent.
|
|
Laboratory abnormalities
Time Frame: Day 4, Day 6, Day 10, Day 15, Day 24 and Day 34
|
The number and severity of blood chemistry and hematology abnormal findings will be summarized descriptively and compared to baseline.
Clinically significant values/outliers will be listed and commented.
|
Day 4, Day 6, Day 10, Day 15, Day 24 and Day 34
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical cure
Time Frame: Day 4, Day 6, Day 10, Day 15, Day 24 and Day 34
|
Clinical cure will be measured based on clinical signs and symptoms and radiological findings.
|
Day 4, Day 6, Day 10, Day 15, Day 24 and Day 34
|
|
Reduction in bacterial count
Time Frame: Day 4, Day 6, Day 10, Day 15, Day 24 and Day 34
|
Reduction in CFU/mL (colony forming unit /mL) of Pseudomonas aeruginosa in the daily quantitative cultures.
|
Day 4, Day 6, Day 10, Day 15, Day 24 and Day 34
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Antoni Torres, MD PhD, Hospital Clinic, Barcelona, Spain
- Principal Investigator: Evangelos Giamarellos-Bourboulis, MD PhD, Attikon University Hospital, Athens, Greece
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Respiratory Tract Diseases
- Lung Diseases
- Disease Attributes
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Cross Infection
- Iatrogenic Disease
- Healthcare-Associated Pneumonia
- Infections
- Pneumonia
- Respiratory Tract Infections
- Pneumonia, Ventilator-Associated
- Pseudomonas Infections
- Anti-Infective Agents
- Anti-Bacterial Agents
- Murepavadin
Other Study ID Numbers
Other Study ID Numbers
- POL7080-003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.